Skip navigation
BelSU DSpace logo

Please use this identifier to cite or link to this item: http://dspace.bsu.edu.ru/handle/123456789/63668
Title: HRD Testing of Ovarian Cancer in Routine Practice: What Are We DealingWith?
Authors: Kekeeva, Е.
Andreeva, Yu.
Tanas, A.
Kalinkin, A.
Dmitriev, V.
Keywords: medicine
medical genetics
oncology
ovarian cancer
homologous recombination deficiency
BRCA mutation
genomic instability score
tumor purity
pathological response
Issue Date: 2023
Citation: HRD Testing of Ovarian Cancer in Routine Practice: What Are We DealingWith? / Е. Kekeeva, Yu. Andreeva, A. Tanas [et al.] // International Journal of Molecular Sciences. - 2023. - Vol.24, №13.-Art. 10497. - Doi: 10.3390/ijms241310497.
Abstract: Assessment of homologous recombination deficiency (HRD) status is now essential for ovarian cancer patient management. The aim of our study was to analyze the influence of ethnic variations, tumor purity, and neoadjuvant chemotherapy on the determination of HRD scores as well as to evaluate feasibility of HRD testing with the Amoy HRD Focus Assay in routine clinical practice
URI: http://dspace.bsu.edu.ru/handle/123456789/63668
Appears in Collections:Статьи из периодических изданий и сборников (на иностранных языках) = Articles from periodicals and collections (in foreign languages)

Files in This Item:
File Description SizeFormat 
Dmitriev_HRD_Testing_23.pdf915.23 kBAdobe PDFView/Open
Show full item record


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.